Literature DB >> 25745344

The success of surgery in the first 24 hours in patients with esophageal perforation.

Ahmet Sami Bayram1, Mehmet Muharrem Erol1, Huseyin Melek1, Mehmet Ali Colak1, Tayfun Kermenli1, Cengiz Gebitekin1.   

Abstract

OBJECTIVE: Esophageal perforation (EP) is a critical and potentially life-threatening condition with considerable rates of morbidity and mortality. Despite many advances in thoracic surgery, the management of patients with EP is still controversial.
MATERIALS AND METHODS: We retrospectively reviewed 34 patients treated for EP, 62% male, mean age 53.9 years. Sixty-two percent of the EPs were iatrogenic. Spontaneous and traumatic EP rates were 26% and 6%, respectively. Three patients had EP in the cervical esophagus and 31 in the thoracic esophagus.
RESULTS: Mean time to initial treatment was 34.2 hours. Twenty patients comprised the early group <24 h) and 14 patients the late group (>24 h). Management of the EP included primary closure in 30 patients, non-surgical treatment in two, stent in one and resection in one. Mortality occurred in nine of the 34 patients (26%). Mortality was EP-related in four patients. Three of the nine patients that died were in the early group (p<0.05). Mean hospital stay was 13.4 days.
CONCLUSION: EP remains a potentially fatal condition and requires early diagnosis and accurate treatment to prevent the morbidity and mortality.

Entities:  

Keywords:  Esophageal perforation; emergency treatment; thoracic surgery

Year:  2014        PMID: 25745344      PMCID: PMC4341927          DOI: 10.5152/eajm.2014.55

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  18 in total

1.  Management of esophageal perforation.

Authors:  I Okten; A K Cangir; N Ozdemir; S Kavukçu; H Akay; S Yavuzer
Journal:  Surg Today       Date:  2001       Impact factor: 2.549

2.  Surgery in thoracic esophageal perforation: primary repair is feasible.

Authors:  S W Sung; J-J Park; Y T Kim; J H Kim
Journal:  Dis Esophagus       Date:  2002       Impact factor: 3.429

3.  Nonoperative management of esophageal perforations. Is it justified?

Authors:  A Altorjay; J Kiss; A Vörös; A Bohák
Journal:  Ann Surg       Date:  1997-04       Impact factor: 12.969

4.  Thoracic esophageal perforations: a decade of experience.

Authors:  Jeffrey L Port; Michael S Kent; Robert J Korst; Matthew Bacchetta; Nasser K Altorki
Journal:  Ann Thorac Surg       Date:  2003-04       Impact factor: 4.330

5.  Nonoperative treatment of 15 benign esophageal perforations with self-expandable covered metal stents.

Authors:  Andreas Fischer; Oliver Thomusch; Stefan Benz; Ernst von Dobschuetz; Peter Baier; Ulrich T Hopt
Journal:  Ann Thorac Surg       Date:  2006-02       Impact factor: 4.330

6.  Functional outcome after surgical treatment of esophageal perforation.

Authors:  M D Iannettoni; A A Vlessis; R I Whyte; M B Orringer
Journal:  Ann Thorac Surg       Date:  1997-12       Impact factor: 4.330

7.  Esophageal perforation: the importance of early diagnosis and primary repair.

Authors:  Atilla Eroglu; Ibrahim Can Kürkçüogu; Nurettin Karaoganogu; Celal Tekinbaş; Omer Yimaz; Mahmut Başog
Journal:  Dis Esophagus       Date:  2004       Impact factor: 3.429

8.  Treatment and outcomes of oesophageal perforation in a tertiary referral centre.

Authors:  A D Muir; J White; J A McGuigan; K G McManus; A N Graham
Journal:  Eur J Cardiothorac Surg       Date:  2003-05       Impact factor: 4.191

9.  Personal management of 57 consecutive patients with esophageal perforation.

Authors:  Narendar Mohan Gupta; Lileswar Kaman
Journal:  Am J Surg       Date:  2004-01       Impact factor: 2.565

10.  Esophageal perforation: principles of diagnosis and surgical management.

Authors:  Markus Huber-Lang; Doris Henne-Bruns; Bernd Schmitz; Peter Wuerl
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

View more
  1 in total

Review 1.  Regenerative Medicine Strategies for Esophageal Repair.

Authors:  Ricardo Londono; Stephen F Badylak
Journal:  Tissue Eng Part B Rev       Date:  2015-04-30       Impact factor: 6.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.